Rasagiline for parkinson's disease modification
First Claim
1. A method of reducing the rate of progression of Parkinson'"'"'s disease in an early stage Parkinson'"'"'s disease patient, the method comprising periodically administering to an early stage Parkinson'"'"'s disease patient an amount of rasagiline, or a pharmaceutically acceptable salt of rasagiline effective to reduce the rate of progression of Parkinson'"'"'s disease of the early stage Parkinson'"'"'s disease patient.
1 Assignment
0 Petitions
Accused Products
Abstract
A method for modifying Parkinson'"'"'s disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to the patient, thereby modifying the disease. The method includes reducing the rate of progression; delaying the need for symptomatic anti-Parkinsonian therapy; reducing the risk of a Parkinson'"'"'s disease patient requiring symptomatic anti-Parkinsonian therapy; and reducing the functional decline.
90 Citations
98 Claims
-
1. A method of reducing the rate of progression of Parkinson'"'"'s disease in an early stage Parkinson'"'"'s disease patient, the method comprising periodically administering to an early stage Parkinson'"'"'s disease patient an amount of rasagiline, or a pharmaceutically acceptable salt of rasagiline effective to reduce the rate of progression of Parkinson'"'"'s disease of the early stage Parkinson'"'"'s disease patient.
-
2-48. -48. (canceled)
- 49. A method of slowing clinical progression and treating symptoms of Parkinson'"'"'s disease in a Parkinson'"'"'s disease patient comprising administering to the Parkinson'"'"'s disease patient rasagiline or a pharmaceutically acceptable salt of rasagiline in an amount of 1 mg rasagiline per day so as to slow clinical progression and treat the signs and symptoms of Parkinson'"'"'s disease in the patient.
-
50. (canceled)
-
54. (canceled)
-
57. (canceled)
- 67. A method of slowing clinical progression and treating symptoms of Parkinson'"'"'s disease in a Parkinson'"'"'s disease patient comprising periodically administering to the Parkinson'"'"'s disease patient an amount of rasagiline or a pharmaceutically acceptable salt of rasagiline effective to slow clinical progression and treat the signs and symptoms of Parkinson'"'"'s disease in the patient, wherein the Parkinson'"'"'s disease patient is a patient whose Total UPDRS score is more than 25.5.
-
78-93. -93. (canceled)
Specification